Nothing Special   »   [go: up one dir, main page]

BR112016016937A8 - partícula semelhante a vírus ou vírus, pluralidade de vírus isolados ou partículas semelhantes a vírus isoladas, ácido nucleico recombinante, célula adaptada a suspensão isolada, porção ligada a membrana da célula, célula adaptada a suspensão isolada, pluralidade de células adaptadas a suspensão isoladas, e método de identificação de um epítopo de célula t - Google Patents

partícula semelhante a vírus ou vírus, pluralidade de vírus isolados ou partículas semelhantes a vírus isoladas, ácido nucleico recombinante, célula adaptada a suspensão isolada, porção ligada a membrana da célula, célula adaptada a suspensão isolada, pluralidade de células adaptadas a suspensão isoladas, e método de identificação de um epítopo de célula t

Info

Publication number
BR112016016937A8
BR112016016937A8 BR112016016937A BR112016016937A BR112016016937A8 BR 112016016937 A8 BR112016016937 A8 BR 112016016937A8 BR 112016016937 A BR112016016937 A BR 112016016937A BR 112016016937 A BR112016016937 A BR 112016016937A BR 112016016937 A8 BR112016016937 A8 BR 112016016937A8
Authority
BR
Brazil
Prior art keywords
isolated
cell
virus
suspension
isolated suspension
Prior art date
Application number
BR112016016937A
Other languages
English (en)
Other versions
BR112016016937A2 (pt
Inventor
S Hillerich Brandan
Chaparro Rodolfo
D Iii Seidel Ronald
C Almo Steven
Original Assignee
Albert Einstein College Medicine Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Albert Einstein College Medicine Inc filed Critical Albert Einstein College Medicine Inc
Publication of BR112016016937A2 publication Critical patent/BR112016016937A2/pt
Publication of BR112016016937A8 publication Critical patent/BR112016016937A8/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1774—Immunoglobulin superfamily (e.g. CD2, CD4, CD8, ICAM molecules, B7 molecules, Fc-receptors, MHC-molecules)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C12N15/867—Retroviral vectors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70539—MHC-molecules, e.g. HLA-molecules
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C12N15/625—DNA sequences coding for fusion proteins containing a sequence coding for a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6881—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for tissue or cell typing, e.g. human leukocyte antigen [HLA] probes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56966—Animal cells
    • G01N33/56972—White blood cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
    • G01N2333/08—RNA viruses
    • G01N2333/15—Retroviridae, e.g. bovine leukaemia virus, feline leukaemia virus, feline leukaemia virus, human T-cell leukaemia-lymphoma virus
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
    • G01N2333/08—RNA viruses
    • G01N2333/15—Retroviridae, e.g. bovine leukaemia virus, feline leukaemia virus, feline leukaemia virus, human T-cell leukaemia-lymphoma virus
    • G01N2333/155—Lentiviridae, e.g. visna-maedi virus, equine infectious virus, FIV, SIV
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A90/00—Technologies having an indirect contribution to adaptation to climate change
    • Y02A90/10—Information and communication technologies [ICT] supporting adaptation to climate change, e.g. for weather forecasting or climate simulation

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Cell Biology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Urology & Nephrology (AREA)
  • Microbiology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Analytical Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Virology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Food Science & Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Plant Pathology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)

Abstract

os métodos e sistemas para a identificação eficiente e sistemática do repertório de epítopos de células t.
BR112016016937A 2014-01-21 2015-01-21 partícula semelhante a vírus ou vírus, pluralidade de vírus isolados ou partículas semelhantes a vírus isoladas, ácido nucleico recombinante, célula adaptada a suspensão isolada, porção ligada a membrana da célula, célula adaptada a suspensão isolada, pluralidade de células adaptadas a suspensão isoladas, e método de identificação de um epítopo de célula t BR112016016937A8 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201461929651P 2014-01-21 2014-01-21
PCT/US2015/012160 WO2015112541A2 (en) 2014-01-21 2015-01-21 Cellular platform for rapid and comprehensive t-cell immunomonitoring

Publications (2)

Publication Number Publication Date
BR112016016937A2 BR112016016937A2 (pt) 2017-08-08
BR112016016937A8 true BR112016016937A8 (pt) 2018-12-18

Family

ID=53682115

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112016016937A BR112016016937A8 (pt) 2014-01-21 2015-01-21 partícula semelhante a vírus ou vírus, pluralidade de vírus isolados ou partículas semelhantes a vírus isoladas, ácido nucleico recombinante, célula adaptada a suspensão isolada, porção ligada a membrana da célula, célula adaptada a suspensão isolada, pluralidade de células adaptadas a suspensão isoladas, e método de identificação de um epítopo de célula t

Country Status (11)

Country Link
US (2) US20170176435A1 (pt)
EP (1) EP3096774B1 (pt)
JP (1) JP6875126B2 (pt)
KR (1) KR102488477B1 (pt)
CN (1) CN106132428B (pt)
AU (1) AU2015209540B2 (pt)
BR (1) BR112016016937A8 (pt)
CA (1) CA2936352A1 (pt)
IL (1) IL246685B (pt)
SG (1) SG11201605632SA (pt)
WO (1) WO2015112541A2 (pt)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2931949B1 (en) 2012-12-11 2019-09-18 Albert Einstein College of Medicine Methods for high throughput receptor/ligand identification
JP2019522466A (ja) 2016-05-18 2019-08-15 アルバート アインシュタイン カレッジ オブ メディシン，インコーポレイティド 変異ｐｄ−ｌ１ポリペプチド、ｔ細胞調節多量体ポリペプチド、及びそれらの使用方法
US11505591B2 (en) 2016-05-18 2022-11-22 Cue Biopharma, Inc. T-cell modulatory multimeric polypeptides and methods of use thereof
IL266696B2 (en) 2016-12-22 2023-04-01 Cue Biopharma Inc Multimeric polypeptides modulate t cells and methods for their use
EP3565829A4 (en) 2017-01-09 2021-01-27 Cue Biopharma, Inc. MULTIMER POLYPEPTIDES T-LYMPHOCYTE MODULATORS AND THEIR METHODS OF USE
JP2020514375A (ja) 2017-03-15 2020-05-21 キュー バイオファーマ， インコーポレイテッド 免疫応答を調節するための方法
WO2018187190A1 (en) * 2017-04-06 2018-10-11 Albert Einstein College Of Medicine, Inc. Precision activation of hiv-specific ctls to eliminate reactived latent t cells
GB201706121D0 (en) * 2017-04-18 2017-05-31 Glaxosmithkline Ip Dev Ltd Stable cell lines for retroviral production
CN107099603A (zh) * 2017-05-31 2017-08-29 成都克里斯博生物科技有限公司 肿瘤免疫t细胞检测试剂盒和检测方法
TW201920248A (zh) * 2017-09-07 2019-06-01 美商信號生物製藥公司 多聚體ｔ細胞調節多肽及其使用方法
CA3074839A1 (en) 2017-09-07 2019-03-14 Cue Biopharma, Inc. T-cell modulatory multimeric polypeptide with conjugation sites and methods of use thereof
EP3737689A4 (en) 2018-01-09 2021-12-01 Cue Biopharma, Inc. MULTIMERIC T CELL-MODULATING POLYPEPTIDES AND METHOD OF USING THEREOF
CA3129316A1 (en) * 2019-02-12 2020-08-20 Pact Pharma, Inc. Compositions and methods for identification of antigen specific t cells
US12061187B2 (en) * 2019-05-23 2024-08-13 Massachusetts Institute Of Technology Ligand discovery and gene delivery via retroviral surface display
IL296209A (en) 2020-05-12 2022-11-01 Cue Biopharma Inc Multimeric t-cell modulatory polypeptides and methods of using them
WO2022056014A1 (en) 2020-09-09 2022-03-17 Cue Biopharma, Inc. Mhc class ii t-cell modulatory multimeric polypeptides for treating type 1 diabetes mellitus (t1d) and methods of use thereof
WO2022159866A2 (en) * 2021-01-25 2022-07-28 The Regents Of The University Of California Methods and compositions for the labeling and selection of antigen-specific t-cells
CA3236366A1 (en) * 2021-10-27 2023-05-04 Xiaojun Lian Universal stem cell and uses thereof

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040253632A1 (en) * 2000-05-25 2004-12-16 Sunol Molecular Corporation Modulation of T -cell receptor interactions
CA2463310A1 (en) * 2001-06-04 2002-12-12 Ml Laboratories Plc Compositions and methods for high-level, large-scale production of recombinant proteins
US20030017134A1 (en) * 2001-06-19 2003-01-23 Technion Research And Development Foundation Ltd. Methods and pharmaceutical compositions for immune deception, particularly useful in the treatment of cancer
US8895020B2 (en) * 2002-04-19 2014-11-25 Washington University Single chain trimers and uses therefor
AU2003901876A0 (en) * 2003-04-17 2003-05-08 The Macfarlane Burnet Institute For Medical Research And Public Health Viral vector
CA2567814C (en) * 2004-05-27 2013-07-23 Jon A. Weidanz Antibodies as t cell receptor mimics, methods of production and uses thereof
US7977457B2 (en) * 2006-05-19 2011-07-12 Teva Pharmaceutical Industries Ltd. Fusion proteins, uses thereof and processes for producing same
EP1889851A1 (en) * 2006-08-18 2008-02-20 Charite Universitätsmedizin-Berlin PAX2 and PAX8 as targets for immunologic and molecular tumour treatment strategies
EP2184070A1 (en) * 2008-11-07 2010-05-12 Hla-G Technologies HLA-G proteins and pharmaceutical uses thereof
WO2012127464A2 (en) * 2011-03-23 2012-09-27 Gavish-Galilee Bio Applications Ltd Constitutively activated t cells for use in adoptive cell therapy
CA2887486A1 (en) * 2012-11-30 2014-06-05 Roche Glycart Ag Removal of cancer cells by circulating virus-specific cytotoxic t-cells using cancer cell targeted mhc class i comprising multi-function proteins

Also Published As

Publication number Publication date
BR112016016937A2 (pt) 2017-08-08
CN106132428A (zh) 2016-11-16
US20230052675A1 (en) 2023-02-16
JP6875126B2 (ja) 2021-05-19
CN106132428B (zh) 2021-08-06
EP3096774A2 (en) 2016-11-30
AU2015209540A8 (en) 2016-08-18
AU2015209540A1 (en) 2016-07-28
CA2936352A1 (en) 2015-07-30
US20170176435A1 (en) 2017-06-22
SG11201605632SA (en) 2016-08-30
EP3096774B1 (en) 2021-03-24
WO2015112541A3 (en) 2015-12-03
AU2015209540B2 (en) 2021-05-13
KR20170002366A (ko) 2017-01-06
KR102488477B1 (ko) 2023-01-13
IL246685B (en) 2020-03-31
EP3096774A4 (en) 2017-09-06
JP2017506882A (ja) 2017-03-16
IL246685A0 (en) 2016-08-31
WO2015112541A2 (en) 2015-07-30
WO2015112541A8 (en) 2016-09-09

Similar Documents

Publication Publication Date Title
BR112016016937A8 (pt) partícula semelhante a vírus ou vírus, pluralidade de vírus isolados ou partículas semelhantes a vírus isoladas, ácido nucleico recombinante, célula adaptada a suspensão isolada, porção ligada a membrana da célula, célula adaptada a suspensão isolada, pluralidade de células adaptadas a suspensão isoladas, e método de identificação de um epítopo de célula t
BR112016020287A2 (pt) células resistentes a vírus e usos das mesmas
BR112017009728A2 (pt) anticorpos isolados, ácido nucleico isolado, vetor, célula hospedeira, método para produzir o anticorpo, composição, usos de um anticorpo e métodos de tratamento de um distúrbio
BR112018002600A2 (pt) células para imunoterapia modificadas para direcionamento ao antígeno cd38 e para inativação do gene cd38
IL251261A0 (en) Reagents and methods for the identification, enrichment and/or expansion of antigen-specific T-cells
CR20180435A (es) Sistema y método para la verificación de la autenticidad de la información de documentos
BR112016023625A2 (pt) dispositivos fluídicos, sistemas e métodos para encapsular e particionar reagentes, e aplicações dos mesmos
PH12017500727A1 (en) Modified virus-like particles of cmv
BR112015021281A2 (pt) métodos de recuperação de césio ou rubídio de minério secundário
EP3210130A4 (en) Data clustering system, methods, and techniques
MX2016016713A (es) Procesos y sistemas para el montaje de secuencias de acido nucleico.
AR105187A1 (es) Aparato, método y sistema para preparación automatizada de explantes y método de uso
EP3494471A4 (en) SYSTEMS AND METHODS FOR SECURELY RESTORING A HOST SYSTEM CODE
EP3529144A4 (en) SYSTEMS AND METHODS FOR AUTOMATED, AIR-CARRIED LIGHTER-THAN AIR PLATFORM
EP3174463A4 (en) Devices, systems and methods for gravity-enhanced microfluidic collection, handling and transferring of fluids
MX2017007196A (es) Fibroblastos de embrion de pollo inmortalizados.
BR112018073238A2 (pt) vírus oncolíticos compreendendo esrage e métodos de tratamento de câncer
EP3186392A4 (en) In-field dna extraction, detection and authentication methods and systems therefor
EP3241298A4 (en) Systems and methods for information recovery from redundancy version packets
MX2017008096A (es) Pestivirus.
BR112017013613A2 (pt) reator quiímico catalítico com separação de partículas e separador de partículas
EP3206132A4 (en) File access method, system and host
SG10201807572PA (en) Robust antibody purification
MX2016013584A (es) Parvovirus porcino.
EP3130905A4 (en) Microparticle separation chip, and microparticle separation system and microparticle separation method which employ said microparticle separation chip

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07G Grant request does not fulfill article 229-c lpi (prior consent of anvisa) [chapter 7.7 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B25A Requested transfer of rights approved

Owner name: ALBERT EINSTEIN COLLEGE OF MEDICINE (US)

B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL.MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL.